Richard found his prostate cancer at an executive physical. Stage II. Highly treatable, good prognosis, the kind of outcome that makes a urologist genuinely pleased instead of just professionally reassuring. “We found this early because you came in regularly,” the urologist told him — the line every doctor in that room says to every patient in that chair. “In another year or two, this conversation would have been much harder.” Richard was fifty-three. Hadn’t been sick a day in four years. No symptoms. Not one.
He wouldn’t have seen a doctor at all if his company’s HR director hadn’t more or less forced the screening protocol on the executive team as a condition of the benefits package. He resented that conversation at the time. Grateful for it for the rest of his life.
Executive health screening — executive physical, comprehensive health assessment, executive wellness examination, pick your marketing term — sits in a strange spot in medicine. It’s simultaneously one of the highest-value preventive interventions available and one of the most inconsistently delivered. Some of it is real. Some of it is theater dressed up in a nice robe with your name embroidered on it.
The industry that’s grown up around “executive health programs” — Mayo, Cleveland Clinic, a hundred boutique concierge outfits in between — offers wildly variable value depending on what’s actually in the panel and how intelligently someone bothers to personalize it. A lot of them don’t bother.
This piece lays out, plainly, what actually has evidence behind it — which tests move the needle on outcomes, what the screening schedule should look like by age and risk factor, and how to size up the programs selling themselves in this space. It doesn’t assume a $10,000 annual physical is on the table. It assumes the reader wants to know what actually matters, and what’s just billing.
WHAT THE POPULATION DATA ACTUALLY SUPPORTS
The whole premise of health screening rests on one clinical idea: disease caught early is more treatable than disease caught late. True for some conditions. Barely true, or not true at all, for others — a distinction the screening industry is not in a hurry to advertise.
The United States Preventive Services Task Force — USPSTF — is the most rigorous evidence body evaluating preventive care in the country. Its grades, A through D, run on evidence quality and net benefit. They’re the closest thing to a gold standard for which screening interventions actually reduce morbidity and mortality at the population level.
Here’s the part that matters and gets glossed over constantly: USPSTF doesn’t just ask whether a screen detects disease. It asks whether detecting it earlier actually changes the outcome. Different question. Harder question. A lot of screening tests fail it quietly.
The Grade A and B recommendations relevant to the executive population: colorectal cancer screening (colonoscopy, stool-based testing, or CT colonography) starting at forty-five; blood pressure checked at every visit; a lipid panel for cardiovascular risk in adults forty and up; diabetes screening (fasting glucose or HbA1c) for overweight or obese adults forty to seventy; cervical cancer screening with Pap smear and HPV co-test for women twenty-one to sixty-five; mammography for women forty to seventy-four; lung cancer screening with low-dose CT for heavy smokers fifty to eighty; hepatitis C screening for adults eighteen to seventy-nine; HIV screening fifteen to sixty-five; depression screening for everyone.
The interesting part of the executive-health conversation starts exactly where it goes past this list — into tests with real value in specific populations, tests that aren’t evidence-supported as universal screens, or tests deployed in ways that require someone who actually knows what they’re reading. This is where a well-run executive physical earns its fee. It’s also where a badly-run one manufactures expensive anxiety for a living.
CARDIOVASCULAR RISK — THE THING THAT ACTUALLY KILLS HIGH-ACHIEVERS
Cardiovascular disease is still the leading cause of death, in the U.S. and everywhere else, and the executive lifestyle does it no favors: chronic stress (HPA axis activation, cortisol driving visceral fat and hypertension), sitting for a living, sleep deprivation, and the kind of nutrition that happens by accident during a bad quarter.
Lipid panel interpretation has moved a long way in the last decade. Total cholesterol, HDL, LDL — still useful, still worth having. But advanced panels give considerably more to work with. ApoB — apolipoprotein B — is now widely recognized as a better predictor of cardiovascular risk than LDL cholesterol, because it counts the actual number of atherogenic particles (LDL, IDL, VLDL, Lp(a)) instead of just measuring the cholesterol riding inside them.
A man can have “normal” LDL and still have elevated ApoB, if his LDL particles run small and dense. It’s called discordance. It quietly underestimates risk in anyone whose doctor only ordered the standard panel and called it a day.
Lipoprotein(a) — Lp(a) — is genetically determined, not touched by statins, and elevated in roughly 20% of the population. Strong independent risk factor for cardiovascular disease, heart attack, stroke, aortic valve stenosis. Worth measuring at least once in a lifetime. Earlier if there’s a family history of premature cardiovascular disease.
An elevated Lp(a) changes the risk math, can push lipid-lowering targets more aggressive, and factors into the emerging Lp(a)-specific therapies — RNA-targeting drugs including inclisiran and pelacarsen — currently in late-stage trials.
C-reactive protein — specifically the high-sensitivity CRP assay, hsCRP — measures systemic inflammation, a cardiovascular risk factor that stands apart from lipids entirely. Elevated hsCRP (above 2.0 mg/L), absent acute infection or inflammatory disease, tracks with meaningfully higher cardiovascular risk and can shift the threshold for starting a statin in someone sitting in intermediate-risk territory.
The JUPITER trial showed statin therapy cut cardiovascular events in people with normal LDL but elevated hsCRP. Which is the whole argument, right there, for treating hsCRP as an actionable marker rather than a curiosity sitting at the bottom of the lab report.
Coronary artery calcium scoring — a low-dose CT that measures calcium deposits directly in the coronary arteries, a physical readout of plaque burden. A CAC of zero tracks with very low ten-year event risk, even with traditional risk factors sitting there on paper, and can support holding off on a statin. A CAC above 300 Agatston units flips that entirely and usually supports more aggressive treatment.
For the “intermediate risk” crowd — 10-20% ten-year risk by the standard calculators, the genuinely ambiguous zone where nobody’s sure whether the statin conversation is warranted — CAC scoring is a Grade B USPSTF recommendation that actually resolves the ambiguity. Radiation dose is low, about 1 mSv, roughly a cross-country flight.
METABOLIC ASSESSMENT — THE PART FASTING GLUCOSE MISSES
Standard diabetes screening with fasting glucose alone misses about 30% of people who actually have diabetes, and a larger share of people with prediabetes, because fasting glucose only captures the baseline — not the dynamic response to a carbohydrate load. HbA1c averages glucose over three months, which helps, but it still misses the guy whose average looks fine and whose postprandial swings are a mess.
The oral glucose tolerance test — OGTT, two-hour post-load glucose — catches more than fasting glucose alone, and it’s been standard in obstetric care for gestational diabetes for decades, so this isn’t experimental technology. For an executive worried about metabolic health, a one-time OGTT tells you considerably more than fasting glucose or HbA1c by themselves. Two-hour post-load glucose over 140 mg/dL is impaired glucose tolerance — prediabetes. Over 200 is diabetes.
A meaningful share of men with “normal” fasting glucose have impaired glucose tolerance sitting there on the OGTT, invisible until someone actually orders the test.
Fasting insulin — not part of a standard metabolic panel, and worth asking for specifically — allows calculation of HOMA-IR: fasting glucose (mg/dL) times fasting insulin (μIU/mL), divided by 405. Above 2.5 suggests insulin resistance heading toward prediabetic. Above 3.5, clinically significant. This number can flag insulin resistance years before glucose or HbA1c ever crosses a threshold — which is exactly the window where lifestyle change works and medication is often avoidable.
Continuous glucose monitoring for non-diabetics has become an executive-health fixture through Levels Health, Supersapiens, Signos and the like. Two to four weeks of CGM data maps glucose variability, postprandial response to specific foods, how sleep quality and exercise move the numbers, and insulin-resistance patterns that standard labs simply don’t catch.
The evidence that CGM-guided behavior change actually improves outcomes in non-diabetics is still thin — it’s a diagnostic tool here, not a proven therapeutic one — but the raw information is real, and it can motivate change in a way an annual lab draw never will.
HORMONES — THE PERFORMANCE FACTOR NOBODY MEASURES
Testosterone in men drops roughly 1-2% a year after thirty, faster with obesity, sleep apnea, chronic stress, or a sedentary life. Clinically significant deficiency — hypogonadism — affects something like 4-5 million American men. Diagnosed in far fewer, because testing is inconsistent and the symptoms get waved off.
Fatigue, reduced libido, foggy concentration, mood shifts, shrinking muscle, growing gut fat — all nonspecific, all routinely filed under “normal aging” or “stress” by a doctor with seven minutes and a full waiting room. Total testosterone, free testosterone (the biologically active fraction), SHBG, and LH are the core panel. Ask for all four. Not just one.
Confirmed hypogonadism — total testosterone under 300 ng/dL with symptoms — treated properly can transform quality of life and metabolic health. The murkier “low-normal” range, 300-500 ng/dL with symptoms present, deserves a real conversation with an endocrinologist or men’s health specialist rather than a shrug.
Thyroid testing — TSH, free T4, ideally free T3 — catches both overt and subclinical thyroid disease, one of the most common and most frequently missed endocrine problems in medicine. Subclinical hypothyroidism (elevated TSH, normal free T4) shows up in something like 4-8% of adults and drags along fatigue, cognitive impairment, elevated cholesterol, and cardiovascular risk. All of it directly relevant to whether an executive can actually think straight by 3pm.
TSH alone can miss subclinical hyperthyroidism — normal TSH with suppressed free T3. Free T3 and T4 give the fuller picture. Worth insisting on both.
Cortisol isn’t a standard screening test, but it’s worth measuring here given how central the HPA axis is to stress resilience and actual performance under pressure. A 24-hour urine free cortisol or, at minimum, a morning salivary cortisol establishes a baseline. Chronically elevated cortisol predicts metabolic syndrome, cardiovascular disease, cognitive decline. None of that is controversial.
Chronically suppressed cortisol — “adrenal fatigue,” a term the wellness industry has beaten to death and oversold to anyone with a pulse and a credit card, but which describes something real underneath the marketing: HPA axis dysregulation, hypothalamic adaptation to chronic stress — shows up as fatigue, a blunted stress response, cognitive fog. Neither extreme is good. Both have real intervention options, but only after someone bothers to diagnose which one it actually is instead of guessing.
CANCER SCREENING — EVIDENCE VERSUS ANXIETY THEATER
This is where the gap between evidence-based medicine and anxiety-driven over-testing gets widest. Comprehensive executive physicals at some prestigious institutions throw in whole-body MRI, full-body CT, sprawling tumor marker panels — tests with limited evidence of improving outcomes and real potential to cause harm once the false positives start a cascade nobody asked for.
Whole-body MRI has been marketed hard as the comprehensive “early detection” answer, with companies like Ezra and Prenuvo charging $1,000-3,000 a session. The evidence for a mortality benefit in asymptomatic, low-risk adults is essentially nonexistent. No randomized controlled trial shows it reduces cancer mortality. None. Anywhere.
What is well documented: the incidental finding rate. Somewhere around 40-50% of whole-body MRIs on healthy adults turn up something requiring follow-up — which triggers a cascade of more imaging, biopsies, procedures, most of it confirming something benign, all of it exposing the patient to radiation, procedural risk, and a level of anxiety that has its own cost nobody bills for.
There’s a word for this now — “incidentaloma,” an unexpected finding on a scan that wasn’t looking for it. Radiology and surgery both know this problem intimately. The industry selling these scans is less eager to bring it up.
The screening that does have evidence, by tumor type: colorectal cancer (colonoscopy every ten years, stool-based tests annually, or CT colonography every five years, average-risk adults forty-five and up — USPSTF Grade A); breast cancer (mammography every two years for women forty to forty-nine, annually fifty to fifty-four based on individual decision, every two years fifty-five to seventy-four — Grade B); cervical cancer (Pap smear every three years, twenty-one to sixty-five, or Pap plus HPV co-test every five years, thirty to sixty-five — Grade A); lung cancer (annual low-dose CT, fifty to eighty, twenty-plus pack-year smoking history — Grade B); prostate cancer (PSA testing, forty-five to sixty-nine, after an actual informed-decision conversation about benefits and harms — Grade C, meaning the decision is individual and the evidence doesn’t clear the bar for a blanket recommendation).
The PSA conversation deserves its own paragraph, because it’s genuinely contested and most men never hear the contested part. The two largest randomized trials — the European ERSPC and the American PLCO — landed on different results. ERSPC showed reduced prostate cancer mortality from screening. PLCO showed none.
Meta-analyses land somewhere around one to two prostate cancer deaths prevented per thousand men screened over ten to fifteen years — at the cost of real overdiagnosis and overtreatment of indolent cancers that would never have caused a symptom, let alone a death, in that man’s lifetime. For a man in a genuinely high-risk category — family history, African American ethnicity, BRCA2 mutation — the math tilts toward screening.
For average-risk men in their forties and fifties, this is a shared-decision conversation with a physician who actually understands the evidence. Not a box checked on an executive panel because that’s what the panel has always included.
NEUROLOGICAL AND COGNITIVE ASSESSMENT
Cognitive screening — catching the early changes that can precede neurodegenerative disease — barely existed in comprehensive physicals a decade ago. Its arrival now tracks with two things: real growth in Alzheimer’s biomarker testing, and the genuine value of simply having a personal baseline on record.
Baseline testing with validated instruments — MoCA (Montreal Cognitive Assessment) or CNS Vitals, a computerized battery across cognitive domains — in your forties gives you something to compare future results against. This matters because reference ranges are population-based. A man who’s intellectually sharp at baseline can show meaningful personal decline while still landing “within normal range” for the general population. The population norm hides exactly the decline that matters to him.
Serial testing against your own baseline catches early cognitive change far better than a single comparison against population norms ever will.
Alzheimer’s biomarker testing — plasma amyloid-beta 42/40 ratio, plasma phosphorylated tau-217, APOE genotyping — is becoming clinically available and is starting to show up in some executive programs. Whether it’s clinically useful for someone with zero symptoms is still an open question, genuinely, not a rhetorical one.
APOE4 genotyping identifies people with substantially elevated Alzheimer’s risk — homozygotes run something like ten to fifteen times the risk of an APOE3/3 person — but there’s no proven disease-modifying treatment to offer once you know. Just the same lifestyle interventions (exercise, sleep, cardiovascular risk management) that benefit literally everyone regardless of genotype. The psychological weight of a positive result with nothing concrete to do about it is significant, and the decision to test at all should follow real genetic counseling, not curiosity on a Tuesday afternoon.
The actionable output of any neurological assessment doesn’t require a biomarker at all: regular aerobic exercise (the single most potent known neuroprotective intervention, consistently tied to reduced dementia risk), consistent sleep, management of hypertension, diabetes, and cholesterol — the major modifiable dementia risk factors — and staying cognitively engaged.
The executive who just does these things starting in his forties is doing more for his long-term cognitive health than any panel of biomarkers could tell him to do.
THE SCREENING SCHEDULE, BY AGE
Ages 35-44: annual blood pressure; lipid panel with ApoB and Lp(a) (measure Lp(a) once); fasting glucose or HbA1c; complete blood count; comprehensive metabolic panel; TSH; testosterone with free testosterone (men); hsCRP; Vitamin D (25-OH); annual skin exam by a dermatologist; hearing assessment if there’s exposure history; depression screening; dental exam twice a year.
Ages 45-54: everything above, plus colorectal cancer screening initiated (colonoscopy preferred for high-risk or high-value individuals; stool-based tests are a reasonable alternative for average risk); mammography initiated (women); PSA discussion (men); CAC scoring if intermediate cardiovascular risk; OGTT if there’s any metabolic concern; DEXA for body composition and bone density, particularly women; sleep study referral if there are apnea symptoms; ophthalmology exam for glaucoma and early macular degeneration.
Ages 55-64: everything above, plus lung cancer screening CT if smoking history meets criteria; echocardiogram if cardiac symptoms or elevated cardiovascular risk; DEXA bone density baseline for postmenopausal women; cognitive baseline (MoCA or equivalent); abdominal aortic ultrasound for men with any smoking history, one-time; carotid intima-media thickness ultrasound if cardiovascular risk is intermediate-to-high.
Ages 65+: ongoing age-appropriate screening per USPSTF; a careful medication review for polypharmacy risk; fall risk and physical function testing; frailty assessment where relevant; annual influenza and RSV vaccination; pneumococcal vaccination; shingles vaccination if not already done.
CHOOSING A PROGRAM — WHAT SEPARATES THE REAL ONES FROM THE THEATER
The executive physical market runs from genuinely high-value programs at academic medical centers down to expensive, superficial “wellness theater” that produces a beautiful binder of results and changes absolutely nothing about the outcome. Sizing these programs up means applying the same skepticism to a medical vendor that anyone would apply to any other vendor pitching a five-figure annual contract.
Signs of real value: physician-led, not just handled by a nurse practitioner or PA, especially for the complex risk-stratification conversations; personalized to actual risk factors and family history instead of a standardized battery run on everyone regardless of relevance; includes real time with the physician to review results and next steps, not just a binder handed over at checkout; refers out to subspecialists when indicated instead of pretending to handle everything in-house; includes nutrition, exercise, and psychological assessment by people actually qualified in those domains; and treats USPSTF and professional-society guidelines as the floor, explaining clearly why and for whom anything additional is being recommended.
Signs it’s theater: marketing that leans on how much testing is included rather than the quality of clinical judgment applied to it; tests with no established outcome benefit in asymptomatic people (whole-body MRI as routine screening, sprawling tumor marker panels, genetic tests with no clear actionability); pricing that sells the luxury of the facility harder than the expertise of the physician; and zero follow-up — a single visit, no continuity, see you next year maybe.
QUESTIONS EXECUTIVES ACTUALLY ASK
At what age should screening start?
Establish a relationship with an internist or primary care physician and get baseline numbers — blood pressure, lipids, glucose, thyroid, CBC, CMP — in your early thirties. Sooner if there’s family history of cardiovascular disease, diabetes, or cancer.
The heavier screening protocols make the most sense starting at forty-five, when colorectal screening becomes standard, advanced cardiovascular testing (CAC, ApoB) becomes genuinely actionable, and enough metabolic risk has usually accumulated to justify the full workup. Before forty: annual blood pressure, cholesterol, glucose, plus appropriate cancer screening for your sex and whatever your lifestyle-specific risk factors demand. That’s the foundation. Build on it.
What’s the one blood test most executives are missing?
ApoB. Consistently underused relative to how much it actually tells you. A standard lipid panel measures LDL cholesterol, and LDL cholesterol can look deceptively low in someone with a high particle count made of small, dense LDL — the discordance problem again. ApoB measures the actual particle count and consistently outpredicts LDL alone in prospective studies. It’s cheap — typically $15-40 standalone — widely available, and belongs in every cardiovascular risk workup.
If the only lipid data on file is a standard panel, ask for ApoB at the next blood draw. It tells a story the LDL number can’t.
How do I get my doctor to take comprehensive screening seriously?
Anchor the conversation in specifics, not a vague request for “everything.” “My father had a heart attack at fifty-two, I want to discuss advanced cardiovascular risk assessment” does more work than “I want all the tests.” Specific asks — ApoB, Lp(a), CAC if intermediate risk, OGTT if metabolic concerns exist, testosterone if fatigue and related symptoms are present — are reasonable, evidence-grounded requests any competent primary care physician should engage with directly, not brush off.
If the current physician won’t engage, find one who practices preventive or integrative medicine, or specializes in executive health. They tend to have the bandwidth for this conversation that a standard seven-minute visit doesn’t allow.
How do I read an abnormal result without spiraling?
Abnormal results need probability-calibrated interpretation, and that’s the physician’s job, not Google’s. What’s the false-positive rate on this specific test? What’s the pre-test probability given demographics and risk factors? What’s the actual next diagnostic step? An elevated PSA, for instance, carries a false-positive rate around 75% for prostate cancer — most men with an elevated PSA do not have prostate cancer. Most.
An elevated TSH needs a repeat test before anyone acts on it — transient elevation from illness or lab variability is common and meaningless on its own. The correct response to an abnormal screen is structured follow-up per clinical guidelines. Not a spiral into worst-case assumptions at eleven at night on a health forum. Keep a personal file of results so trend, not any single number, becomes the thing that’s actually tracked.
Is concierge medicine worth the money?
Concierge medicine — direct primary care with a retainer, typically $150-500 a month, same-day appointments, longer visits, direct access to the physician — earns its cost for a few specific reasons in the executive context: acute concerns get addressed fast instead of getting deferred through a busy quarter; longer appointments allow an actual conversation about complex health optimization instead of the standard seven-minute primary care sprint; and continuity with one physician who knows the full picture beats episodic visits with whoever happens to be available that week.
The cost — $2,000-6,000 a year — compares well against prevented chronic disease, avoided emergency care, and the very real cognitive and performance cost of health problems left to fester. For a high-earning executive, it’s a reasonable investment in the one piece of infrastructure everything else runs on.
The executive who treats his own body with less rigor than his company’s annual audit is making an asymmetric mistake. Companies audit because you can’t manage what you don’t measure. The same logic applies to the human system that runs the company.
Richard’s treatment worked. Four years cancer-free now. He sits on the board of the company he retired from, and in that seat he pushed through a comprehensive executive health program as a standard benefit for senior leadership — not a perk, a requirement. Three other executives found significant cardiovascular risk factors that got managed before anything happened. One found early-stage diabetes. The program runs $1,200 per person per year. Richard does not consider that expensive.
He knows what expensive actually looks like. It looks like a diagnosis at stage III instead of stage II. It looks like a stroke in a fifty-one-year-old CEO who never had his blood pressure checked because he “felt fine.” It looks like preventable. And it looks like a choice somebody made not to check.
MENTAL HEALTH SCREENING IN THE EXECUTIVE CONTEXT
Validated depression screening — the PHQ-9 (nine items) and PHQ-2 (the ultra-brief two-item version) — is the gold standard in primary care and a USPSTF Grade B recommendation for every adult. Takes three minutes. Sensitivity and specificity both around 88% for major depressive disorder.
The problem in executive populations isn’t the tool. It’s the honesty going into it. High achievers routinely score low on depression screening not because they’re not depressed, but because they can see exactly which answers trigger a follow-up conversation and route around them. Which is why the relationship, and the psychological safety in the room, matters for executive mental health screening in a way it simply doesn’t for a cholesterol number.
Anxiety screening with the GAD-7 (seven items) does the parallel work. In executive populations, anxiety frequently shows up as hypervigilance, perfectionism, an inability to delegate, and a nervous system that can’t disengage from work — patterns that get relabeled, constantly, as conscientiousness and work ethic instead of what they actually are. Catching it usually requires a clinician who understands high-performance contexts and won’t wave off achievement-oriented anxiety as “just normal stress.” A lot of them will. Push past that one.
ADHD deserves its own mention here, because its prevalence in this population is substantially higher than recognized, it presents differently in adults than the childhood criteria used to diagnose it, and its effects on executive function — working memory, impulse control, time management, follow-through — are directly relevant to how someone actually performs at work. The Adult ADHD Self-Report Scale (ASRS) is well-validated and available.
A meaningful share of high-achieving executives carry ADHD that went undiagnosed in childhood — high intelligence compensated for the early impairments right up until cognitive demand exceeded what compensation could cover. Proper evaluation, and treatment where appropriate, behavioral or pharmacological or both, can produce real gains in quality of life and professional performance.
GENETIC TESTING — CLINICAL VALUE VERSUS CONSUMER ANXIETY MACHINE
Direct-to-consumer genetic testing is everywhere now, and it’s increasingly bundled into executive health programs. The clinical value swings wildly by specific gene, variant, and context — and consumer reports have a bad habit of putting a genuinely significant variant right next to one that carries a trivial relative risk on a large population background, generating anxiety with no proportionate action attached to it.
Clinically significant genetic testing falls into clear buckets. BRCA1/2 for breast and ovarian cancer risk — validated, actionable (prophylactic surgery, enhanced surveillance), appropriate for anyone with personal or family history of BRCA-associated cancers. Lynch syndrome (MSH2, MLH1, and related genes) — appropriate with personal or family history of colorectal or endometrial cancer at a young age.
APOE genotyping for Alzheimer’s risk, discussed above, is increasingly available but demands real genetic counseling before and after, given the psychological weight of a positive result with no definitive treatment attached.
Pharmacogenomic testing — how genetic variants affect drug metabolism, mostly CYP450 enzyme polymorphisms — has genuine clinical value for medication selection in psychiatry, where CYP2D6 and CYP2C19 variants dramatically change how commonly used antidepressants and antipsychotics get metabolized. If psychiatric medication is on the table, pharmacogenomic testing can meaningfully guide drug selection and dosing, and insurance is increasingly covering it for that reason.
Consumer testing — 23andMe, AncestryDNA, the rest — is entertainment with a side of population genetics data. It can pick up some of the clinically significant variants mentioned above, but it is not a replacement for clinical genetic counseling and medical-grade testing. The health sections in these reports mix variants with large effects (BRCA, APOE4) alongside variants that nudge relative risk by a hair — dozens of common SNPs — in ways that need real interpretation, not a scroll through an app.
If a consumer test flags something potentially significant, the correct next move is confirmatory medical-grade testing with genetic counseling. Not a decision made off the consumer report alone at midnight.
The intelligent approach to genetic testing: test when there’s a specific clinical question and established actionability — BRCA with a family history that warrants it, pharmacogenomics if psychiatric medication selection is on the table, Lynch syndrome with a relevant colorectal history. Don’t go looking for hidden time bombs through broad genomic screening. The false-positive rate and the psychological weight of ambiguous findings outweigh the benefit when there’s no specific indication driving the test in the first place.
A physician trained in clinical genetics, or working alongside a genetic counselor, is the right guide through this field. Not a direct-to-consumer marketplace optimized to sell the next kit.
THE PERSONAL HEALTH RECORD — THE MOST BORING HIGH-VALUE THING ON THIS LIST
One of the most practically useful, and least discussed, pieces of executive health management is just keeping a longitudinal record of your own numbers. Most people interact with the healthcare system episodically — data scattered across providers, systems, years — which makes trend analysis nearly impossible and risks losing clinically significant context between one doctor and the next.
A proper personal health record includes: complete vaccination history; every screening result with dates and reference ranges; blood pressure readings, ideally serial — one reading tells you almost nothing, a pattern tells you everything; every lab result since adulthood; medication and supplement history; surgical and hospitalization history; family medical history through second-degree relatives (the piece most frequently lost, and the piece that most directly affects screening and risk decisions); and any imaging results with the original reports attached.
Digital platforms — Apple Health with medical record integration, portals like CommonWell, or honestly just a well-kept spreadsheet — make this far more practical than it used to be.
Two or three hours spent organizing historical health data into something coherent pays off at every clinical encounter afterward. Being able to answer “what was your PSA last year?” or “when did your father have his heart attack?” with a number instead of a guess changes the quality of the decisions made in that room.
The trend analysis this enables is not a minor convenience. A fasting glucose that goes 88, then 96, then 102, then 107 over four years — each value individually “normal,” but the trajectory is unmistakably headed toward prediabetes — is immediately visible in a longitudinal record. Invisible in four separate annual checkups with four different snapshots and no memory connecting them. Catching it this way can mean intervention five years earlier than a single measurement would ever trigger.
Same logic for LDL climbing from 110 to 130 to 145 across three annual measurements — a trend that’s actionable well before the absolute number crosses any treatment threshold. The healthcare system was not built to hand you this longitudinal view automatically. Somebody has to maintain it. Either the patient does it himself, or he pays a concierge physician who does it for him.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map